This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs
by Kinjel Shah
Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion
by Zacks Equity Research
Bristol-Myers' (BMY) multiple myeloma drug, Empliciti gets approval in Europe in combination with Celgene's Pomalyst in third or later-line settings.
Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.
Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?
by Zacks Equity Research
Amgen's (AMGN) purchase of Celgene's blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space.
Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
by Zacks Equity Research
Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen Presents Positive Data From Rituxan Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) markets Mvasi and Kanjinti, biosimilar versions of Avastin and Herceptin, respectively in the United States, and Kanjinti and Amgevita, biosimilar of Humira, in the EU.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Synlogic Discontinues Development of SYNB1020, Stock Down
by Zacks Equity Research
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Here's Why Allergan is Outperforming Its Industry Of Late
by Zacks Equity Research
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
by Zacks Equity Research
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
by Zacks Equity Research
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
Should Value Investors Consider AbbVie (ABBV) Stock Now?
by Zacks Equity Research
Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
by Zacks Equity Research
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Top Research Reports: Chevron, AbbVie, Phillips 66 & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), AbbVie (ABBV) and Phillips 66 (PSX).
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Momenta (MNTA) reports a wider loss and misses on sales in Q2 .
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.